Abstract
It was with great interest we read the recent review titled ‘Drug transport across the blood-brain-barrier'.1 In this paper, Pardridge describes the challenge of bypassing the blood–brain barrier (BBB) to allow therapeutic molecules to access the central nervous system (CNS), a challenge long recognized as one of the major issues in developing new treatments for brain disorders. The paper focused on how molecules can be reengineered for BBB transport via carrier-mediated transport and molecular ‘Trojan horse' delivery to access receptor-mediated transfer systems within the BBB, an interesting and exciting approach to this problem.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
